louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05348824: Effect of Moringa Oleifera Leaf Extract on Postoperative Pain and Bacterial Reduction in Mandibular Premolars
Official title: Effect of Moringa Oleifera Leaf Extract Versus Sodium Hypochlorite as Root Canal Irrigant on Postoperative Pain and Bacterial Reduction in Mandibular Premolars With Necrotic Pulps: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Necrotic Pulp
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-04-27
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to clinically compare the intensity of post-operative pain and the amount of bacterial reduction after using Moringa oleifera leaf extract solution during chemo-mechanical preparation, versus 2.5% NaOCl, in asymptomatic necrotic mandibular premolars treated in a single visit


Eligibility criteria: Inclusion Criteria:

1. Systematically healthy patient (ASA I,II).
2. Age between 20 and 55 years
3. Male or female.
4. Asymptomatic mandibular premolar teeth diagnosed with pulp necrosis with apical periodontitis.
5. Radiographic examination using Digora intraoral periapical sensor plate and software (Digora; Soredex, Helsinki, Finland) showing mandibular premolars with (smaller than 3 mm (0-2 mm)) periapical radiolucency.

Exclusion Criteria:

1. Medically compromised patients having significant systemic disorders. (ASA III or IV).
2. History of intolerance to NSAIDS.
3. Teeth with:

   * Immature roots
   * Vital pulp tissues.
   * Association with swelling.
   * Acute peri-apical abscess or acute exacerbation of a chronic abscess.
   * Mobility Grade II or III.
   * Previously accessed or endodontically treated
   * Deep periodontal pockets more than 4 mm
   * Vertical root fractures, coronal perforation, calcification, and external or internal root resorptions.
4. Patients who could not interpret the NRS.
5. Patients with diabetes, immune-compromising, and immunosuppression disease and pregnant women were, also, excluded.

Primary outcomes:
measure: Postoperative pain
timeFrame: up to 48 hours postoperatively
Secondary outcomes:
measure: Intracanal bacterial load change
timeFrame: First sample is taken at Time 0 "T0" then second sample taken after chemo-mechanical preparation on 15 minutes at Time 1 "T1".
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05497024: Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing
Official title: Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Prostate Cancer
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: American Cancer Society, Inc.
First posted: 2022-08-11
Enrollment: 45
Sex: MALE
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: M D Anderson Cancer Center

Brief summary: This protocol describes development and user testing of an educational shared decision making intervention to help men with prostate cancer who are on active surveillance make decisions with their health care providers about if and when to de-escalate surveillance testing. The project is important because for many patients their cancer does not progress to the point of needed curative treatment or their health status changes such that they are no longer good candidates for treatment. For these men, de-escalating ongoing surveillance (e.g., fewer biopsies or imaging studies) is a reasonable option.

Detailed description: Objectives:

The overall goal of this protocol is to develop and refine an educational tool for use by patients and health-care providers to help men with localized prostate cancer make informed decisions about discontinuation of active surveillance.

* Conduct cognitive and initial usability and acceptability testing of a prototype decision aid with patients
* Conduct cognitive and initial usability and acceptability testing of a prototype decision aid with care partners/caregivers
* Conduct expert reviews of a prototype decision aid with clinicians

Eligibility criteria: Patients

Inclusion Criteria:

1. Males aged 65 or older
2. Diagnosis of localized prostate cancer
3. On active surveillance for 12 or more months
4. Fluent in English

Exclusion Criteria:

1. Receiving treatment for another cancer (primary or recurrence)

Caregivers

Inclusion Criteria:

1. Aged 18 or older
2. Fluent in English
3. Involved with the care of an eligible patient (i.e. partner, close friend, family member, companion)

   Exclusion Criteria:
4. None

Clinicians

Inclusion Criteria:

1. Aged 18 or older
2. Fluent in English
3. Provides clinical care for patients with prostate cancer (e.g. medical oncologists, urologists, radiation oncologists, nurse practitioners, physician assistants)

Exclusion Criteria:

1. None

Primary outcomes:
measure: The Ottawa Acceptability Scale
timeFrame: through study completion and average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Lisa Lowenstein, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05903924: Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
Official title: Motion Serifos: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness During Travel
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Motion Sickness
Lead sponsor: Vanda Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2023-06-15
Enrollment: 316
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel


Eligibility criteria: Inclusion Criteria:

* History of motion sickness
* Age 18-75

Exclusion Criteria:

* Nausea-inducing disorder other than motion sickness
* BMI\>40
* History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

Primary outcomes:
measure: Prevention of Vomiting Measured by Vomiting Assessment (VA)
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Pacific Research Partners
state: California
city: San Jose
country: United States
facility: Lumos Clinical Research
state: California
city: Santa Monica
country: United States
facility: Santa Monica Clinical Trials
state: California
city: Boston
country: United States
facility: Beacon Clinical Research
state: Massachusetts
city: New York
country: United States
facility: Manhattan Medical Research
state: New York
Study officials:
References:
Clinical trial NCT00185224: Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive
Official title: A Single-center, Open-label, Controlled, Randomized Study to Investigate the Impact of a Sequential Oral Contraceptive (SH T00658ID) as Compared to a Sequential Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D00264A) on Plasma Lipids, Hemostatic Variables, and Carbohydrate Metabolism in Healthy Female Volunteers Aged 18-50 Years Over 7 Treatment Cycles, Including the Pharmacokinetics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Contraception
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2005-09-16
Enrollment: 58
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to confirm the safety of SH T00658ID with regard to plasma lipids, hemostatic variables, and carbohydrate metabolism. In addition, the pharmacokinetic parameter following the long term administration of SH T00658ID will be assessed.

Detailed description: The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Eligibility criteria: Inclusion Criteria:

* Healthy female volunteers between 18 and 50 years requiring contraception

Exclusion Criteria:

* Pregnancy or lactation
* Any conditions that might interfere with the outcome as well as all contraindications for OC use

Primary outcomes:
measure: Impact on metabolic parameters (e.g. hemostatic parameters) after 6 month treatment
timeFrame: Baseline, Cycle 7
Secondary outcomes:
measure: Measurement of PK parameters
timeFrame: Cycle 4, Cycle 7
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Bayer Schering Pharma AG - Clin. Pharm. Berlin
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
citation: Junge W, Mellinger U, Parke S, Serrani M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31(8):573-584. doi: 10.2165/11590220-000000000-00000.
Clinical trial NCT03107624: Clinical Presentations Before AMI Onset and Coronary Atherosclerosis
Official title: Pre-infarction Angina and Culprit Plaque Characteristics in Patients With STEMI
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Myocardial Infarction
Lead sponsor: Harbin Medical University
Sponsor class: OTHER
First posted: 2017-04-11
Enrollment: 305
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: AMI patients

Brief summary: This study aimed to evaluate the incidence of preinfarction angina in AMI patients and test the hypothesis that different clinical presentations before AMI onset can affect coronary plaque morphologies in AMI patients .

Detailed description: Patients with AMI who underwent primary percutaneous coronary intervention（PCI） and optical coherence tomography (OCT) examination is expected to be included in this study.Data about history were prospectively collected by a standard questionaire ,especially regarding the detail information about preinfarction angina.The basic clinical characteristics,angiographic and OCT findings are compared between patients with and without preinfarction angina.

Eligibility criteria: Inclusion Criteria：

1. Men or non-pregnant women \>18 years of age and \< 85 years of age;
2. Patients undergo cardiac catheterization for AMI;
3. Patients able to provide written informed consent.

Exclusion Criteria:

1. Patients cant afford medical history;
2. Cardiac shock；
3. Severe left ventricular dysfunction;
4. Left main disease;
5. Hepatic or kidney dysfunction;
6. OCT was performed after predilation;
7. Poor OCT image or massive thrombus.

Primary outcomes:
measure: Difference in culprit lesion morphologies assessed by OCT according to the presence or absence of PIA
timeFrame: baseline
Secondary outcomes:
measure: In-hospital outcomes after AMI.
timeFrame: baseline
Other outcomes:
Locations:
city: Harbin
country: China
facility: The 2nd Affiliated Hospital of Harbin Medical University
state: Heilongjiang
Study officials:
affiliation: The Second Affiliated Hospital of Harbin Medical University
name: Bo Yu, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03652324: What Should be the Anesthesia Method in Endobronchial Coil Treatment
Official title: Comparison of General Anesthesia and Deep Sedation in Enbronchial Coil Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coil Treatment
Deep Sedation
Keywords: coil treatment
general anesthesia
deep sedation
Lead sponsor: TC Erciyes University
Sponsor class: OTHER
Collaborators: name: Bozok University
First posted: 2018-08-29
Enrollment: 32
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This prospective, randomize study was conducted in a university hospital. Bronchoscopic lung volume reduction (BLVR) coil treatment has recently been introduced into clinical practice as an alternative for patients chronic obstructive pulmonary disease (COPD) with severe refractory heterorogenous emphysema to conventional medical treatment. Thirty two patients diagnosed with (COPD) with severe refractory heterorogenous emphysema undergoing BLVR coil treatment were included in the study. Seventeen procedure were performed under general anesthesia and fifteen procedure were performed under deep sedation-analgesia. in the general anesthesia group peak pressure, air leakage and end-tidal carbon dioxide were recorded. In the both groups pulse oximeter, transcutaneous carbondioxide, recovery time, bronchospasm, laryngospasm, pneumothorax, massive bleeding were recorded.


Eligibility criteria: Inclusion Criteria:

* patients diagnosed with COPD with undergoing BLVR coil treatment.

Exclusion Criteria:

* patients who refuse to participate in the study

Primary outcomes:
measure: recovery time measurement
timeFrame: 2 hours
measure: complication rate
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Yozgat
country: Turkey
facility: Bozok University
state: Eyalet/Yerleşke
Study officials:
References:
Clinical trial NCT05356624: Mobilization With Movement Versus Soft Tissue Mobilization in Patients With De Quervain Tenosynovitis
Official title: Effects of Mobilization With Movement Versus Soft Tissue Mobilization on Pain Function and ROM in Patients With De Quervain Tenosynovitis: A Randomised Controlled Trail
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: De Quervain Syndrome
Keywords: de quervains tenosynovitis
pain
manual therapy
ROM
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-05-02
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: this study will investigate the effects of mobilization with movement in addition to soft tissue mobilization on pain and range of motion in patients suffering from De Quervain Tenosynovitis.

Detailed description: De quervain tenosynovitis also known as stenosing tenosynovitis is a condition which occur when tendons at the base of thumb pinched and become irritated. Several treatment options are available like ultrasound, Graston therapy, thrust or non-thrust manipulation, mobilization with movement, soft tissue mobilization but this study focus on 2 treatments to improve malalignment of the joint and also reduce pain. First treatment is mobilization with movement in which passive accessory mobilization from therapist while active mobility is performed by patient. Second technique is soft tissue mobilization in which passive glides are applied. The purpose of study is to make comparison between mobilization with movement and soft tissue mobilization.

Eligibility criteria: Inclusion Criteria:

* Male and female

  * 20 to 50 years
  * Subjects with pain in base of thumb (9)
  * Subject with positive fienklstein test

Exclusion Criteria:

* History of radiculopathy

  * History of systemic illness
  * History of connective tissue disorder
  * Rheumatoid arthritis
  * History of hand or wrist injury or acute trauma
  * Subject with negative fienklstein test

Primary outcomes:
measure: Visual analogue scale
timeFrame: 3 months
measure: Goniometry
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Gujrat
country: Pakistan
facility: Aziz Bhatti Shaheed hospital
state: Punjab
Study officials:
affiliation: Riphah International University
name: Nosheen Manzoor, MS-OMPT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05552924: Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
Official title: The Effect of Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Epilepsy
Keywords: Self Acupressure
Fatigue
Sleep Quality
Epilepsy Patients
Lead sponsor: Ataturk University
Sponsor class: OTHER
First posted: 2022-09-23
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study is an experimental study with pre-test and post-test control groups
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to examine the effect of Self-acupressure application on fatigue and sleep quality in epilepsy patients.

Detailed description: Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in our body in order to ensure the continuation and balance of the energy in our body.

Eligibility criteria: Inclusion Criteria:

* Being over 18 years old
* Volunteering to participate in the research
* Having the ability to use technological tools
* Not having a verbal communication disability (hearing and speaking)
* Not having a diagnosed psychiatric disorder
* Having a scale score of \>5 on the Piper Fatigue Scale
* A score of \>5 on the Pittsburgh Sleep Quality Scale

Primary outcomes:
measure: The Piper Fatigue Scale
timeFrame: At the end of Sessions 1 (each Session 2 days a week)
measure: The Piper Fatigue Scale
timeFrame: At the end of Sessions 16 (each Session 2 days a week)
measure: Pittsburgh Sleep Quality Index (PSQI)
timeFrame: At the end of Sessions 1 (each Session 2 days a week)
measure: Pittsburgh Sleep Quality Index (PSQI)
timeFrame: At the end of Sessions 16 (each Session 2 days a week)
Secondary outcomes:
Other outcomes:
Locations:
city: Elazıg
country: Turkey
facility: Firat University
Study officials:
affiliation: Firat University
name: Gülcan Bahçecioğlu Turan, PhD
role: STUDY_DIRECTOR
References:
citation: Wang T, Zhang Q, Xue X, Yeung A. A systematic review of acupuncture and moxibustion treatment for chronic fatigue syndrome in China. Am J Chin Med. 2008;36(1):1-24. doi: 10.1142/S0192415X08005540.
Clinical trial NCT05529524: Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)
Official title: Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Follicular Lymphoma
Keywords: Follicular Lymphoma
Mosunetuzomab
Resistance
CD20-CD3
Bispecific antibodies
Neoplasms
Lymphatic Diseases
Immunoproliferative Disorders
Lead sponsor: The Lymphoma Academic Research Organisation
Sponsor class: OTHER
Collaborators: name: Roche Pharma AG
First posted: 2022-09-07
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients who participate to CELESTIMO study (NCT04712097)

Brief summary: Mosunetuzumab is a T-cell bispecific antibody targeting CD20 and CD3 aiming to redirect T cells to engage and eliminate malignant B cells. Bispecific antibodies (BsAb) are a promising treatment option which can induce long-term responses in refractory and relapsed B cell lymphoma patients. However, the factors determining the quality and duration of responses are poorly understood.

Detailed description: the objective is to produce a collection of great scientific interest for lymphoma research from CELESTIMO's clinical trial patients' samples to increase knowledge of treatment with mosunetuzumab's for patients with follicular lymphoma (FL).

study population involves patients participating to CELESTIMO study in France. 10 sites are expected in this biobanking protocol study

Biological samples will collected as part of routine care (tissue and blood already sampled in routine and/or CELESTIMO study) at screening, at C4, at C12 or at progressive disease/relapse.

Eligibility criteria: patients who participate to CELESTIMO study (NCT04712097)

Primary outcomes:
measure: Capacity of sampling
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bayonne
country: France
facility: Centre Hospitalier de La Cote Basque; Hematologie
city: Lille
country: France
facility: Hopital Claude Huriez; Hematologie
city: Marseille
country: France
facility: Institut Paoli Calmettes
city: Montpellier
country: France
facility: CHU Saint Eloi; Service d'Hématologie Clinique
city: Nantes cedex 1
country: France
facility: CHU NANTES - Hôtel Dieu; Service d'Hematologie Clinique
city: Nîmes
country: France
facility: CHU de Nîmes - Hôpital Carémeau
city: Paris
country: France
facility: Hopital Saint Antoine; Hematologie Clinique
city: Poitiers
country: France
facility: Hopital De La Miletrie; Hematologie Et Oncologie Medicale
city: Rennes
country: France
facility: CHU Pontchaillou
Study officials:
affiliation: Oncopole - Toulouse France
name: Camille Laurent, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Micro-environnement et cancer (MICA) - Rennes France
name: Karin Tarte, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Centre Hospitalier Universitaire de Lille - Lille France
name: Franck MORSCHHAUSER, MD
role: PRINCIPAL_INVESTIGATOR
References: